Get the Stockscreener App
5.38
0.19%
-0.010
After Hours:
5.38
Generation Bio Co stock is traded at $5.38, with a volume of 200.57K.
It is down -0.19% in the last 24 hours and down -0.74% over the past month.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
See More
Previous Close:
$5.39
Open:
$5.28
24h Volume:
200.57K
Relative Volume:
3.36
Market Cap:
$36.25M
Revenue:
$21.23M
Net Income/Loss:
$-72.42M
P/E Ratio:
-0.7944
EPS:
-6.7728
Net Cash Flow:
$-81.69M
1W Performance:
+0.00%
1M Performance:
-0.74%
6M Performance:
+35.18%
1Y Performance:
-53.62%
1-Day Range:
$5.2001
$5.54
1-Week Range:
$5.2001
$5.64
52-Week Range:
$3.004
$12.50
Generation Bio Co Stock (GBIO) Company Profile
Name
Generation Bio Co
Sector
Industry
Phone
857-529-5908
Address
301 BINNEY STREET, CAMBRIDGE
Compare GBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GBIO
Generation Bio Co
|
5.38 | 36.32M | 21.23M | -72.42M | -81.69M | -6.7728 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.96 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.36 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
851.42 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.17 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
200.67 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Generation Bio Co Stock (GBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Dec-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Feb-18-21 | Initiated | Needham | Buy |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jul-07-20 | Initiated | Jefferies | Buy |
| Jul-07-20 | Initiated | Wedbush | Outperform |
View All
Generation Bio Co Stock (GBIO) Latest News
Generation Bio (GBIO) Rating Update: Wedbush Upgrades to Outperf - GuruFocus
NodThera appoints Geoff McDonough, M.D., as independent board member - marketscreener.com
GBIO Downgraded by Jefferies with Price Target Cut by 54.55% | G - GuruFocus
‘Zombie’ biotech buyer Xoma to acquire Generation Bio - BioPharma Dive
Wedbush Upgrades Generation Bio to Outperform From Neutral, Adjusts Price Target to $5.50 From $7 - marketscreener.com
Jefferies Downgrades Generation Bio to Hold From Buy, Adjusts Price Target to $5 From $11 - marketscreener.com
Jefferies downgrades Generation Bio stock to Hold as XOMA acquisition announced - Investing.com Nigeria
XOMA Strikes Deal To Acquire Generation Bio, Expanding Royalty Portfolio - Nasdaq
XOMA Royalty to Acquire Generation Bio - citybiz
Shareholder Alert: The Ademi Firm investigates whether Generation Bio Co. is obtaining a Fair Price for its Public Shareholders - PR Newswire
GBIO Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Generation Bio Co. is Fair to Shareholders - The AI Journal
Generation Bio Announces Merger with XOMA Royalty - TipRanks
Xoma Royalty enters into agreement to acquire Generation Bio - marketscreener.com
XOMA to Acquire Generation Bio (GBIO) in Strategic Merger - GuruFocus
XOMA Royalty Corporation to Acquire Generation Bio Co. in Cash Transaction with Milestone and Royalty Opportunities - Quiver Quantitative
Generation Bio (NASDAQ: GBIO) agrees to XOMA cash plus CVR takeover - Stock Titan
Generation Bio (NASDAQ: GBIO) agrees to $4.29 sale to XOMA Royalty plus CVR - Stock Titan
Generation Bio (GBIO) to be acquired in planned XOMA tender offer - Stock Titan
XOMA Royalty Corporation entered into an agreement to acquire Generation Bio Co. for $28.92 million. - marketscreener.com
Published on: 2025-12-14 17:13:04 - moha.gov.vn
What analysts say about Generation Bio Co stockTechnical Resistance Breaks & Master Stock Selection - earlytimes.in
Generation Bio (GBIO) Price Target Increased by 13.40% to 30.94 - MSN
Is Generation Bio Co. stock gaining market share2025 Investor Takeaways & Safe Capital Growth Stock Tips - Newser
How Generation Bio Co. stock performs in weak economyJuly 2025 Decliners & Fast Gaining Stock Strategy Reports - Newser
Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing - Via TT
Is Generation Bio Co. stock overvalued by current metricsWall Street Watch & Fast Gaining Stock Strategy Reports - Newser
What catalysts could drive Generation Bio Co. stock higherPrice Action & Free Technical Confirmation Trade Alerts - Newser
Generation Bio (GBIO) Stock Analysis Report | Financials & Insights - Benzinga
Here's Why We're A Bit Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation - Yahoo Finance
Layoff Tracker: Valneva Terminates 30 Amid Site Closure - BioSpace
Can Generation Bio Co. stock sustain institutional interest2025 Institutional Moves & Consistent Growth Equity Picks - moha.gov.vn
CEO McDonough Acquires 366 Of Generation Bio Co [GBIO] - TradingView
[Form 4] Generation Bio Co. Insider Trading Activity - Stock Titan
Can Generation Bio Co. stock surprise with earnings upsideMarket Growth Summary & Real-Time Chart Breakout Alerts - newser.com
Will Generation Bio Co. stock deliver consistent dividendsPortfolio Return Report & Long-Term Growth Plans - newser.com
Why Generation Bio Co. stock remains a top recommendationGap Down & Real-Time Stock Entry Alerts - newser.com
Why Generation Bio Co. stock remains resilientWeekly Risk Summary & Weekly Setup with High ROI Potential - newser.com
Using data models to predict Generation Bio Co. stock movement2025 Stock Rankings & Growth Oriented Trading Recommendations - newser.com
Ranking Generation Bio Co. among high performing stocks via toolsWeekly Stock Analysis & Risk Managed Investment Strategies - newser.com
How Generation Bio Co. stock reacts to inflationary pressuresWeekly Stock Analysis & Safe Capital Investment Plans - newser.com
Heatmap analysis for Generation Bio Co. and competitorsPortfolio Value Report & Risk Adjusted Swing Trade Ideas - newser.com
Is Generation Bio Co. stock poised for growthMarket Performance Report & Growth Focused Investment Plans - newser.com
Generation Bio Co. Reports Strategic Restructuring and Financial Highlights - MSN
Why Generation Bio Co. stock could see breakout soonSell Signal & High Return Trade Opportunity Guides - newser.com
Generation Bio Co Stock (GBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):